Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EBIT (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed EBIT for 15 consecutive years, with -$7.8 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 37.74% to -$7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.0 million through Dec 2025, down 0.64% year-over-year, with the annual reading at -$49.0 million for FY2025, 0.64% down from the prior year.
  • EBIT hit -$7.8 million in Q4 2025 for Cardiff Oncology, up from -$12.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5.4 million in Q1 2021 to a low of -$14.8 million in Q2 2025.
  • Historically, EBIT has averaged -$10.6 million across 5 years, with a median of -$10.9 million in 2023.
  • Biggest five-year swings in EBIT: crashed 103.49% in 2022 and later skyrocketed 37.74% in 2025.
  • Year by year, EBIT stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then fell by 10.01% to -$10.3 million in 2023, then decreased by 21.68% to -$12.6 million in 2024, then surged by 37.74% to -$7.8 million in 2025.
  • Business Quant data shows EBIT for CRDF at -$7.8 million in Q4 2025, -$12.0 million in Q3 2025, and -$14.8 million in Q2 2025.